Market openNon-fractional
Cogent Biosciences/COGT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cogent Biosciences
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Ticker
COGT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
164
Website
www.cogentbio.com
COGT Metrics
BasicAdvanced
$914M
Market cap
-
P/E ratio
-$2.48
EPS
-0.06
Beta
-
Dividend rate
Price and volume
Market cap
$914M
Beta
-0.06
Financial strength
Current ratio
12.046
Quick ratio
11.878
Long term debt to equity
4.047
Total debt to equity
4.386
Management effectiveness
Return on assets (TTM)
-38.43%
Return on equity (TTM)
-65.70%
Valuation
Price to book
4.01
Price to tangible book (TTM)
4.01
Price to free cash flow (TTM)
-4.253
Growth
Earnings per share change (TTM)
8.87%
3-year earnings per share growth
-37.85%
What the Analysts think about COGT
Analyst Ratings
Majority rating from 11 analysts.
COGT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$58M
7.37%
Profit margin
0.00%
NaN%
COGT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.59
-$0.64
-$0.63
-$0.62
-
Expected
-$0.54
-$0.50
-$0.56
-$0.52
-$0.56
Surprise
8.30%
27.80%
11.83%
20.10%
-
COGT News
AllArticlesVideos
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
GlobeNewsWire·3 weeks ago
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
GlobeNewsWire·1 month ago
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cogent Biosciences stock?
Cogent Biosciences (COGT) has a market cap of $914M as of July 05, 2024.
What is the P/E ratio for Cogent Biosciences stock?
The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of July 05, 2024.
Does Cogent Biosciences stock pay dividends?
No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Cogent Biosciences dividend payment date?
Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Cogent Biosciences?
Cogent Biosciences (COGT) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.
Buy or sell Cogent Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.